Is pazopanib/pazopanib a domestic drug or an imported drug?

Pazopanib is an imported targeted drug developed and produced by GlaxoSmithKline (GSK), a world-renowned pharmaceutical company. The drug was first approved for marketing by the U.S. Food and Drug Administration (FDA) in 2009 and has been promoted and used in many countries and regions. It is mainly used to treat advanced renal cell carcinoma (RCC) and specific types of soft tissue sarcoma (STS). Due to its good efficacy and relatively controllable safety, pazopanib has gradually become one of the important choices for targeted treatment of renal cancer and soft tissue sarcoma.

In China, pazopanib initially entered the market as an imported drug and was officially approved by the State Food and Drug Administration in 2018 for the treatment of patients with locally advanced or metastatic renal cell carcinoma. At the same time, domestic generic versions of pazopanib have also been launched, so the imported version of the original research and the domestic generic version are currently sold in the domestic market.

Compared with some domestically produced targeted drugs, the price of pazopanib is relatively high. However, in recent years, with the adjustment of national medical insurance policies, it has been included in the national medical insurance directory, allowing patients to obtain the drug at a lower out-of-pocket cost. In addition, some patients may also choose to purchase drugs overseas, such as generic drugs in India and Bangladesh. However, formal medical institutions usually recommend the use of imported drugs approved by the national drug regulatory department to ensure the reliability of safety and efficacy.

In general, pazopanib was initially an imported drug, but with the improvement of domestic pharmaceutical technology, the existing domestic version has also provided new options for patients. Whether it is an imported or domestic version, doctors will make corresponding treatment suggestions based on the patient's specific conditions.

Reference materials:https://www.votrient.com/